Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Teva Wins FDA Approval For Qnasl Nasal Aerosol To Treat Allergic Rhinitis

3/26/2012 9:17 AM ET

Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA: Quote) on Monday said the U.S. Food and Drug Administration has approved Qnasl Nasal Aerosol, a new, dry nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents who are 12 years old or above.

The approval was based on a comprehensive clinical development program that assessed the product's safety and efficacy in the treatment of seasonal allergic rhinitis and perennial allergic rhinitis in patients 12 years of age and older.

Allergic rhinitis is the most common allergic disease in the U.S. It affects more than one in five people, causing some to have symptoms year round and others to experience symptoms during specific times of the year.

The safety and efficacy of Qnasl Nasal Aerosol was demonstrated in four, Phase III trials, where patients received Qnasl 320 mcg once-daily administered as two sprays in each nostril.

Intra-nasal corticosteroids are recommended as first-line therapy for allergic rhinitis and the only available option on the market before the approval of Qnasl (beclomethasone dipropionate) were aqueous formulations.

The product is expected to be available by prescription in April. It will be the first marketed non-aqueous or dry nasal aerosol in a product category that reports annual sales of $2.5 billion.

Qnasl is delivered as a once-daily, pressurized, hydrofluoroalkane or HFA-propelled non-aqueous aerosol that is environmentally friendly and offers a built-in dose counter.

Gary Gross, practicing allergist and co-founder of the Dallas Asthma and Allergy Center, said, "There are some patients with allergic rhinitis who report dissatisfaction with the currently available therapies. The approval of QNASL offers these patients a safe and effective treatment option with a new dry mode of delivery."

Teva shares, which closed at $43.07 on Friday, are adding 2.1 percent in pre-market activity.

Register
To receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Housing starts in the U.S. showed a notable increase in the month of March, according to a report released by the Commerce Department on Wednesday, although starts still came in well below economist estimates. The report showed that housing starts climbed 2.8 percent to an annual rate of 946,000 in March from the revised February estimate of 920,000. After moving mostly higher over the course of the two previous sessions, stocks may see some further upside in early trading on Wednesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 63 points. The U.K. unemployment rate fell below the 7 percent threshold to a five-year low in February and average earnings finally moved above inflation reducing the squeeze on household finances. The jobless rate came in at 6.9 percent of the labor force, the lowest since February 2009, data from the Office for National Statistics showed Wednesday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.